Dutch contract manufacturer PharmaCell B.V has signed a three-year Manufacturing Services Agreement to make cancer cell therapies for Lion Biotechnologies.
Caligor Opco LLC is providing regulatory and logistical management for Puma Biotechnology’s expanded access program (EAP) for its investigational breast cancer therapy, neratinib.
In the absence of a CRO, the 200 patient NeoART study is relying on the UK NHS, crowdfunding and charity to trial an antimalarial generic for late stage bowel cancer.
Helomics has signed a deal with the diagnostics firm MDNA Life Sciences Inc., to help further develop MDNA’s liquid biopsy platform and commercialize its tests for prostate cancer.
Cryoport’s network of cold chain logistics will support the delivery of Gradalis Inc’s autologous cell therapy to various cancer trial sites across the US.
The NORLUX Neuro-Oncology Laboratory has installed MR Solutions’ preclinical scanner to advance cancer research and translation to clinical applications.
CrownBio’s new stable cell lines feature various immune checkpoints and receptors which are key targets and pathways for oncology drug discovery and development.
Researchers used pre-existing platforms to identify and recruit patients for a cancer research study – connecting advocacy groups, social media, and a dedicated website to register patients.
Combination therapies and collaboration will be key in curing cancer, according to Pfizer which has seen 'astounding progress' in its immuno-oncology partnership with Merck KGaA.
Charles River Laboratories is conducting new studies using animal models to give insight into therapeutic strategies where pharma companies expect to see the most success.
Propanc Health Group Corporation has received $1.2m from an institutional investor in order to fast track preclinical activities for its lead product, PRP.
Crown Bioscience has expanded its portfolio of non-animal based disease models by licensing a range of cellular prostate cancer models developed by UK academics.
Novartis subsidiary Sandoz will commercialise small and large molecule injectables using French delivery tech firm MedinCell’s subcutaneous controlled release platform.
A chemotherapy drug marketed by Eagle Pharmaceuticals has become the first product approved for commercial manufacture from AMRI’s once troubled Burlington facility.
Trial supplies of a radio-immunotherapy drug made by Areva Med in compliance with GMP are stable five years after they were produced according to the results of new analysis.
Epic and LabCorp’s Covance have agreed to extend their partnership to provide circulating tumor cell (CTC) technology and oncology clinical trial support in Asia.
Juniper Pharma Services has won a contract to manufacture ‘sono-sensitive particles’ used to aid delivery of cancer drugs into solid tumours for OxSonics.
Scientists have developed a new way of visualizing multiple myelomas in 3D by replicating tumours in hens’ eggs in a approach they say will aid drugmakers.
Mice engineered to recognise light-emitting markers as self will let cancer drug developers to track tumor growth in animals with functioning immune systems say US researchers.
Ongoing research on two new drug delivery systems could help clinicians more accurately understand how certain tumors react to different treatments, according to the Journal of the American Medical Association.
Aspyrian Therapeutics has selected CDMO Goodwin Biotechnology to complete process development, scale-up, and cGMP manufacturing of their novel antibody drug conjugate (ADC).
Lonza shipped a sample batch of a drug for resistant cancers this week and is set produce commercial supplies if the Phase I candidate goes on to be approved says Sunshine Biopharma.
An anti-fungal drug shows potential to treat a range of cancers, according to research from the Repurposing Drugs in Oncology (ReDO) project, but the drugmakers will need a financial incentive to pursue a licence for new indications.
Research tool supplier Horizon Discovery Group and ArcherDX, a supplier of Next Generation Sequencing (NGS) fusion detection, have signed an Original Equipment Manufacture (OEM) agreement that will see Horizon’s Reference Materials supplied as a standalone...
Cancer Drug firms trying to block protein kinase Cs should rethink say researchers behind a study indicating that the enzymes suppress tumour development.
